Our look is new. Our purpose is the same. Learn more about our brand evolution.
Boston, MA / January 24, 2013 Facioscapulohumeral muscular dystrophy (FSHD) is a disease most people have never heard of, even though it is one of the most common forms of […]
Fueled by funding from the FSH Society, an international research team has discovered the genes that cause facioscapulohumeral muscular dystrophy (FSHD), a devastating muscle-wasting disease that affects 500,000 people around […]
GlaxoSmithKline PLC (GSK) announces partnership to develop therapeutics to treat FSHD. The goal of the new agreement is to develop a small-molecule-based medicine to potentially reverse FSHD
Year-End Challenge to Fund the Treatment for FSHD! A group of long-time supporters have come forward to challenge the Society’s members and friends to make gifts to Fund the Treatment […]
Canadian Foundation Launched! Great news for Canadians who wish to support FSHD research! Canadians can now donate funds directly towards FSHD research — and receive a tax deduction. The FSHD […]
